SINGAPORE (Sept 16): Singapore eDevelopment announced wholly-owned subsidiary, HWH World, has entered into a binding term sheet with Todos Medical for the exclusive marketing rights over two breast cancer screening tests – TM-B1 and TM-B2.
Todos Medical is an Israeli-based in-vitro diagnostics company engaged in the development of blood tests for the early detection of a variety of cancers. The TM-B1 and TM-B2 it developed uses Todos Biomedical Infrared Analyses, a proprietary patented method for cancer screening that makes use of peripheral blood smear analysis and incorporates other disciplines such as biochemistry, physics and signal processing.
Singapore eDevelopment says the collaboration enables Todos Medical to market its breast cancer screening tests to HWH World’s network of members based in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, China, Hong Kong and Taiwan, Africa, Australia, Latin America, Canada and the United States; excluding physicians and hospitals, and excluding consumers who are not members of HWH World’s network of members.
Both the TM-B1 and TM-B2 breast cancer screening tests have received the CE mark, a certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area.
The duo has agreed that Singapore will be the first jurisdiction in which they will partner to launch the operations.
Chan Heng Fai, executive chairman of Singapore eDevelopment and chairman of HWH World, says, “Our two companies are aligned in viewing the significant value in mitigating the need for expensive and invasive biopsies by utilising a blood test that will determine whether a biopsy is necessary.”
Shares in Singapore eDevelopment closed 7.9% higher on Monday at 4.1 cents.
